RESEARCH

Lorem ipsum dolor sit amet, consectetur adipiscing elit

Stem Cell Research Publications

Minimally Invasive Autologous Bone Marrow Concentrate Stem Cells in the Treatment of the Chronically Injured Achilles Tendon: A Case Report
McKenna, R. W., DO & Riordan, N. H., Ph.D

Feasibility of combination allogeneic stem cell therapy for spinal cord injury: a case report

Thomas E. Ichim, Fabio Solano, Fabian Lara, Eugenia Paris, Federico Ugalde, Jorge Paz Rodriguez, Boris Minev, Vladimir Bogin, Famela Ramos, Erik J Woods, Michael P Murphy, Amit N Patel, Robert J Harman, Neil H. Riordan – International Archives of Medicine 2010, 3:30

Cellular therapy for spinal cord injury (SCI) is overviewed focusing on bone marrow mononuclear cells, olfactory ensheathing cells, and mesenchymal stem cells. A case is made for the possibility of combining cell types, as well as for allogeneic use.

Antigen Specific Therapy of Rheumatoid Arthritis

Ichim T. Zheng X, Suzuki M, Kubo N, Zhang X, Min L, Beduhn M, Riordan N, Inman R, Min W. – Expert opin. Biol. Ther. 2008; 8(2): 191-199

Immunotherapy offers the promise of antigen specific suppression of pathological immune responses in conditions such as autoimmunity and organ transplantation. Substantial advances have been made in recent years in terms of understanding basic immunological mechanism of auto reactivity, as well as clinically implementing immune based therapies that are antigen nonspecific.

Autologous Stromal Vascular Fraction Cells: A Tool for Facilitating Tolerance in Rheumatic Disease

Thomas E. Ichim, Robert J. Harman, Wei-Ping Min, Boris Minev, Fabio Solano, Jorge Paz Rodriguez, Doru T Alexandrescu, Rosalia De Necochea-Campion, Xiang Hu, Annette M Marleau, Neil H Riordan – Accepted Manuscript 2010; Cellular Immunology

Immunotherapy offers the promise of antigen specific suppression of pathological immune responses in conditions such as autoimmunity and organ transplantation. Substantial advances have been made in recent years in terms of understanding basic immunological mechanism of auto reactivity, as well as clinically implementing immune based therapies that are antigen nonspecific.

Clinical outcome of autologous bone marrow aspirates concentrate (BMAC) injection in degenerative arthritis of the knee.

Kim JD1, Lee GW, Jung GH, Kim CK, Kim T, Park JH, Cha SS, You YB.

As a treatment method of degenerative arthritis of knee, this study evaluated the clinical efficacy of the intra-articular injection of autologous bone marrow aspirates concentrate (BMAC) with adipose tissue.

Treatment of knee osteoarthritis with autologous mesenchymal stem cells: a pilot study.

Orozco L1, Munar A, Soler R, Alberca M, Soler F, Huguet M, Sentís J, Sánchez A, García-Sancho J.

Osteoarthritis is the most prevalent joint disease and a frequent cause of joint pain, functional loss, and disability. Osteoarthritis often becomes chronic, and conventional treatments have demonstrated only modest clinical benefits without lesion reversal. Cell-based therapies have shown encouraging results in both animal studies and a few human case reports. We designed a pilot study to assess the feasibility and safety of osteoarthritis treatment with mesenchymal stromal cells (MSCs) in humans and to obtain early efficacy information for this treatment.

Establishing proof of concept: Platelet-rich plasma and bone marrow aspirate concentrate may improve cartilage repair following surgical treatment for osteochondral lesions of the talus.

Smyth NA1, Murawski CD, Haleem AM, Hannon CP, Savage-Elliott I, Kennedy JG.

Osteochondral lesions of the talus are common injuries in the athletic patient. They present a challenging clinical problem as cartilage has a poor potential for healing. Current surgical treatments consist of reparative (microfracture) or replacement (autologous osteochondral graft) strategies and demonstrate good clinical outcomes at the short and medium term follow-up. Radiological findings and second-look arthroscopy however, indicate possible poor cartilage repair with evidence of fibrous infill and fissuring of the regenerative tissue following microfracture. Longer-term follow-up echoes these findings as it demonstrates a decline in clinical outcome.

Cancer risk is not increased in patients treated for orthopaedic diseases with autologous bone marrow cell concentrate.

Hernigou P1, Homma Y2, Flouzat-Lachaniette CH1, Poignard A1, Chevallier N1, Rouard H1.

There is concern that regenerative cell-based therapies could result in increased risk of tumor formation. We investigated the long-term risks for systemic and site-specific cancers in patients who had received autologous bone marrow-derived stromal progenitor cells to treat orthopaedic lesions.

Biologic augmentation of rotator cuff repair with mesenchymal stem cells during arthroscopy improves healing and prevents further tears: a case-controlled study.

Hernigou P1, Flouzat Lachaniette CH, Delambre J, Zilber S, Duffiet P, Chevallier N, Rouard H.

The purpose of this study was to evaluate the efficiency of biologic augmentation of rotator cuff repair with iliac crest bone marrow-derived mesenchymal stem cells (MSCs). The prevalence of healing and prevention of re-tears were correlated with the number of MSCs received at the tendon-to-bone interface.

Intralesional autologous mesenchymal stem cells in management of osteonecrosis of femur: a preliminary study.

Rastogi S1, Sankineani SR, Nag HL, Mohanty S, Shivanand G, Marimuthu K, Kumar R, Rijal L.

Management of early stages of osteonecrosis aims to prevent the collapse of the femoral head by attempts at restoring the vascularity of femoral head. Bone marrow-derived mononuclear cells with their angiogenic and osteogenic properties appear to have the potential to halt the disease process when injected intralesionally following core decompression.

Growth and differentiation factor-5 contributes to the structural and functional maintenance of the intervertebral disc.

Feng C1, Liu H, Yang Y, Huang B, Zhou Y.

Intervertebral disc degeneration (IDD) is a widely recognized contributor to low back pain (LBP). The Prevention or reversal of IDD is a potential treatment for LBP. Unfortunately, current treatments for IDD are aimed at relieving symptoms rather than regenerating disc structure or function. Recently, the injection of growth factors and mesenchymal stem cell (MSC) transplantation have been shown to be promising biological therapies for IDD.